Marshall Wace
INDV icon

Marshall Wace’s Indivior Pharmaceuticals INDV Stock Holding History

Marshall Wace’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-647,555
Closed -$23.2M – 3441
2025
Q4 		$23.2M Sell
647,555
-243,534
-27% -$7.44M 0.02% 584
2025
Q3 		$21.5M Buy
+891,089
New +$18.6M 0.02% 626
2025
Q2 		– Sell
-394,841
Closed -$3.76M – 2917
2025
Q1 		$3.76M Sell
394,841
-111,941
-22% -$1.18M ﹤0.01% 1195
2024
Q4 		$6.3M Buy
506,782
+440,072
+660% +$4.53M 0.01% 967
2024
Q3 		$650K Sell
66,710
-7,022
-10% -$82.2K ﹤0.01% 1833
2024
Q2 		$1.19M Buy
73,732
+61,302
+493% +$1.11M ﹤0.01% 1611
2024
Q1 		$266K Buy
+12,430
New +$233K ﹤0.01% 2155

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Marshall Wace's INDV Position: Q1 2026 in Review

Marshall Wace sold out of Indivior Pharmaceuticals (INDV) in Q1 2026, closing a stake of 647,555 shares — an estimated $23.2M sold.

Marshall Wace first reported a position in INDV in Q1 2024 and held it in 7 quarters. The position peaked at $23.2M in Q4 2025. 290 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Marshall Wace reported no remaining Indivior Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 647,555 Indivior Pharmaceuticals shares in Q1 2026, an estimated $23.2M.
  • Marshall Wace first reported a position in Indivior Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • Marshall Wace's Indivior Pharmaceuticals position peaked at $23.2M in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.